Eli Lilly & Co. (LLY) Tops Q2 EPS by 6c; Raises Outlook

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $1.11, $0.06 better than the analyst estimate of $1.05. Revenue for the quarter came in at $5.82 billion versus the consensus estimate of $5.6 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2017 EPS of $4.10-$4.20, versus prior of $4.05-$4.15 and the consensus of $4.12.

"Lilly delivered strong revenue growth in the second quarter, building on the momentum of Trulicity, Taltz and the other new products in our portfolio," said David A. Ricks, Lilly's chairman, president and CEO. "To deliver on our mission and maximize our opportunity, we have four key priorities -- launching with excellence, replenishing the pipeline, driving productivity, and building talent and capability in our core areas of focus."

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• CEMEX, S.A.B. de C.V. (CX) Tops Q1 EPS by 5c
• Equinor ASA (EQNR) Tops Q1 EPS by 22c, misses on revenue